Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium
Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …
Symptoms, complications and management of long COVID: a review
OL Aiyegbusi, SE Hughes, G Turner… - Journal of the Royal …, 2021 - journals.sagepub.com
Globally, there are now over 160 million confirmed cases of COVID-19 and more than 3
million deaths. While the majority of infected individuals recover, a significant proportion …
million deaths. While the majority of infected individuals recover, a significant proportion …
Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19
ATTACC, ACTIV-4a, and REMAP-CAP … - New England Journal …, 2021 - Mass Medical Soc
Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label …
RD Lopes, RHM Furtado, AVS Macedo, B Bronhara… - The Lancet, 2021 - thelancet.com
Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …
Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among …
Importance Thrombotic events are commonly reported in critically ill patients with COVID-19.
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …
Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective To evaluate …
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Summary The International Initiative on Thrombosis and Cancer is an independent
academic working group of experts aimed at establishing global consensus for the treatment …
academic working group of experts aimed at establishing global consensus for the treatment …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of …
Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …
[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
MR O'Donnell, B Grinsztejn… - The Journal of …, 2021 - Am Soc Clin Investig
BACKGROUND Although convalescent plasma has been widely used to treat severe
coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support …
coronavirus disease 2019 (COVID-19), data from randomized controlled trials that support …